List of Sancuso drug patents

Sancuso is owned by Kyowa Kirin.

Sancuso contains Granisetron.

Sancuso has a total of 1 drug patent out of which 0 drug patents have expired.

Sancuso was authorised for market use on 12 September, 2008.

Sancuso is available in film, extended release;transdermal dosage forms.

Sancuso can be used as use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting.

The generics of Sancuso are possible to be released after 22 January, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7608282 KYOWA KIRIN Transdermal granisetron
Jan, 2025

(1 year, 11 months from now)

Drugs and Companies using GRANISETRON ingredient

Market Authorisation Date: 12 September, 2008

Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of SANCUSO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in